ABVC
ABVC BioPharma·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 3
High Gross Profit Margin
Significant Revenue Decline
Significant Net Income Decline
Low Cash Short-term Debt Ratio
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ABVC
Abvc Biopharma, Inc.
A clinical-stage biopharmaceutical company that specializes in oncology, hematology, and ophthamology therapeutic areas
44370 Old Warm Springs Blvd., Fremont, CA 94538
--
ABVC BioPharma, Inc., was incorporated under the laws of the State of Nevada on February 6, 2002. ABVC BioPharma is a clinical-stage biopharmaceutical company with six drugs and one medical device under development (ABV-1701/Vitargus). For its drug products, the company focuses on conducting proof-of-concept trials through Phase 2 of the clinical development process at world-renowned research institutions such as Stanford University, UCSF and Cedars-Sinai Medical Center using its licensed technology. For Vitargus, the company intends to conduct clinical trials in various locations around the world up to the third phase.
Company Financials
EPS
ABVC has released its 2025 Q2 earnings. EPS was reported at -0.13, versus the expected 0, missing expectations. The chart below visualizes how ABVC has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ABVC has released its 2025 Q3 earnings report, with revenue of 795.95K, reflecting a YoY change of 104.47%, and net profit of -1.29M, showing a YoY change of -164.14%. The Sankey diagram below clearly presents ABVC's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
